Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Angela Coliva Liliana Devizzi Ettore Seregni Carmelo Carlo-Stella Marco Maccauro Carlo Chiesa Anna Guidetti |
| Publication date | May 20, 2009 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |